S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
Log in
NASDAQ:PCRX

Pacira BioSciences Stock Forecast, Price & News

$74.45
-4.37 (-5.54 %)
(As of 02/25/2021 12:00 AM ET)
Add
Compare
Today's Range
$73.29
Now: $74.45
$80.00
50-Day Range
$66.08
MA: $72.66
$78.82
52-Week Range
$27.46
Now: $74.45
$80.00
Volume639,186 shs
Average Volume568,601 shs
Market Capitalization$3.23 billion
P/E Ratio26.21
Dividend YieldN/A
Beta1.27
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a non-opioid medication administered at the time of surgery to control pain while reducing opioid requirements; and iovera system, a handheld cryoanalgesia device used to deliver controlled doses of cold temperature only to targeted nerves. The company has collaboration with Aetna. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey.
Pacira BioSciences logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:PCRX
CUSIP69512710
Phone973-254-3560
Employees606
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$421.03 million
Cash Flow$1.75 per share
Book Value$8.51 per share

Profitability

Net Income$-11,020,000.00

Miscellaneous

Market Cap$3.23 billion
Next Earnings Date5/5/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.92 out of 5 stars

Medical Sector

83rd out of 1,957 stocks

Pharmaceutical Preparations Industry

32nd out of 771 stocks

Analyst Opinion: 2.3Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 4.4 5 -4 -3 -2 -1 -
$74.45
-4.37 (-5.54 %)
(As of 02/25/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PCRX News and Ratings via Email

Sign-up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Pacira BioSciences (NASDAQ:PCRX) Frequently Asked Questions

Is Pacira BioSciences a buy right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pacira BioSciences in the last year. There are currently 4 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Pacira BioSciences stock.
View analyst ratings for Pacira BioSciences
or view top-rated stocks.

What stocks does MarketBeat like better than Pacira BioSciences?

Wall Street analysts have given Pacira BioSciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Pacira BioSciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Pacira BioSciences' next earnings date?

Pacira BioSciences is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Pacira BioSciences
.

How were Pacira BioSciences' earnings last quarter?

Pacira BioSciences, Inc. (NASDAQ:PCRX) released its quarterly earnings data on Thursday, October, 29th. The company reported $0.68 EPS for the quarter, topping the consensus estimate of $0.65 by $0.03. The firm earned $117.50 million during the quarter, compared to analyst estimates of $115.95 million. Pacira BioSciences had a trailing twelve-month return on equity of 10.71% and a net margin of 29.95%. Pacira BioSciences's quarterly revenue was up 12.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.48 earnings per share.
View Pacira BioSciences' earnings history
.

How has Pacira BioSciences' stock price been impacted by COVID-19 (Coronavirus)?

Pacira BioSciences' stock was trading at $35.19 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PCRX stock has increased by 111.6% and is now trading at $74.45.
View which stocks have been most impacted by COVID-19
.

What guidance has Pacira BioSciences issued on next quarter's earnings?

Pacira BioSciences updated its FY 2020 Pre-Market earnings guidance on Thursday, January, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $429.6-429.6 million, compared to the consensus revenue estimate of $427.7 million.

What price target have analysts set for PCRX?

11 brokers have issued 12-month price objectives for Pacira BioSciences' shares. Their forecasts range from $48.00 to $90.00. On average, they anticipate Pacira BioSciences' stock price to reach $73.27 in the next year. This suggests that the stock has a possible downside of 1.6%.
View analysts' price targets for Pacira BioSciences
or view top-rated stocks among Wall Street analysts.

Who are Pacira BioSciences' key executives?

Pacira BioSciences' management team includes the following people:
  • Mr. David M. Stack, Chairman & CEO (Age 71, Pay $1.47M)
  • Mr. Charles A. Reinhart III, CPA, M.B.A., Chief Financial Officer (Age 60, Pay $637.22k)
  • Ms. Kristen Williams, Chief Admin. Officer & Sec. (Age 47, Pay $727.97k)
  • Dr. Roy Winston, Chief Clinical Officer (Age 60, Pay $647.06k)
  • Mr. Max Reinhardt, Pres of ROW (Age 50, Pay $619.19k)
  • Ms. Lauren Bullaro Riker, Principal Accounting Officer & VP of Fin. (Age 42)
  • Mr. Charles Laranjeira, Chief Technical Officer (Age 55)
  • Susan Mesco, Head of Investor Relations
  • Mr. Richard Kahr, VP of HR
  • Mr. Robert J. Weiland, Sr. VP of Alliance Management (Age 61)

What is Dave Stack's approval rating as Pacira BioSciences' CEO?

54 employees have rated Pacira BioSciences CEO Dave Stack on Glassdoor.com. Dave Stack has an approval rating of 45% among Pacira BioSciences' employees. This puts Dave Stack in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Pacira BioSciences' key competitors?

What other stocks do shareholders of Pacira BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacira BioSciences investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), Skyworks Solutions (SWKS), AbbVie (ABBV), Pfizer (PFE), QUALCOMM (QCOM), Exelixis (EXEL) and Tesla (TSLA).

What is Pacira BioSciences' stock symbol?

Pacira BioSciences trades on the NASDAQ under the ticker symbol "PCRX."

Who are Pacira BioSciences' major shareholders?

Pacira BioSciences' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (16.34%), Renaissance Technologies LLC (6.04%), Baillie Gifford & Co. (4.52%), Clearbridge Investments LLC (2.60%), Frontier Capital Management Co. LLC (2.38%) and Stephens Investment Management Group LLC (2.23%). Company insiders that own Pacira BioSciences stock include Andreas Wicki, Charles A Reinhart III, Charles Anthony Laranjeira, David M Stack, Dennis Mcloughlin, John P Phd Longenecker, Kristen Marie Williams, Laura Brege, Lauren Bullaro Riker, Mark A Kronenfeld, Max Reinhardt, Paul J Hastings, Richard Scranton and Roy Winston.
View institutional ownership trends for Pacira BioSciences
.

Which major investors are selling Pacira BioSciences stock?

PCRX stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Schroder Investment Management Group, Frontier Capital Management Co. LLC, Nuveen Asset Management LLC, Stephens Investment Management Group LLC, Principal Financial Group Inc., Principal Financial Group Inc., and Glenmede Trust Co. NA. Company insiders that have sold Pacira BioSciences company stock in the last year include Andreas Wicki, Charles A Reinhart III, Charles Anthony Laranjeira, David M Stack, Kristen Marie Williams, Laura Brege, Lauren Bullaro Riker, Max Reinhardt, Paul J Hastings, and Roy Winston.
View insider buying and selling activity for Pacira BioSciences
or view top insider-selling stocks.

Which major investors are buying Pacira BioSciences stock?

PCRX stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Canada Pension Plan Investment Board, Baillie Gifford & Co., Neumeier Poma Investment Counsel LLC, Nicholas Company Inc., Zweig DiMenna Associates LLC, Tamarack Advisers LP, and Assenagon Asset Management S.A.. Company insiders that have bought Pacira BioSciences stock in the last two years include Mark A Kronenfeld, and Roy Winston.
View insider buying and selling activity for Pacira BioSciences
or or view top insider-buying stocks.

How do I buy shares of Pacira BioSciences?

Shares of PCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pacira BioSciences' stock price today?

One share of PCRX stock can currently be purchased for approximately $74.45.

How much money does Pacira BioSciences make?

Pacira BioSciences has a market capitalization of $3.23 billion and generates $421.03 million in revenue each year. The company earns $-11,020,000.00 in net income (profit) each year or $0.86 on an earnings per share basis.

How many employees does Pacira BioSciences have?

Pacira BioSciences employs 606 workers across the globe.

What is Pacira BioSciences' official website?

The official website for Pacira BioSciences is www.pacira.com.

Where are Pacira BioSciences' headquarters?

Pacira BioSciences is headquartered at 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054.

How can I contact Pacira BioSciences?

Pacira BioSciences' mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The company can be reached via phone at 973-254-3560 or via email at [email protected]


This page was last updated on 2/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.